Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
403.1 USD | -1.15% | +4.51% | +31.50% |
May. 29 | Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing | MT |
May. 29 | TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 36.34 and 31.1 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.50% | 12.61B | C+ | ||
+55.55% | 59.34B | B- | ||
+43.17% | 40.24B | A | ||
-4.71% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+13.76% | 27.26B | B- | ||
-22.00% | 19.23B | B | ||
+2.16% | 12.49B | B+ | ||
+25.70% | 12.28B | B+ | ||
-6.25% | 11.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEDP Stock
- Ratings Medpace Holdings, Inc.